Predictive role of midtreatment changes in survivin, gstp1, and topoisomerase 2α expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 36, Issue 3, 2013, Pages 215-223

  Eralp, Yeşim ^a   Keskin, Serkan ^a   Akşk, Ebru ^a   Akşk, Elif ^a   Iǧci, Abdullah ^a   Müslümanoǧlu, Mahmut ^a   Ylmaz, Sabri ^a   Tunac, Mehtap ^a   Çamlca, Hakan ^a   Tuzlal, Stk ^b   Saip, Pnar ^a   Dalay, Nejat ^a   Özmen, Vahit ^a   Topuz, Erkan ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

breast cancer; GSTP1; mRNA; response to neoadjuvant chemotherapy; survivin; topoisomerase 2A

Indexed keywords

CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DOCETAXEL; DOXORUBICIN; GLUTATHIONE TRANSFERASE P1; SURVIVIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; GLUTATHIONE S-TRANSFERASE PI; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878835022     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318243913f     Document Type: Article

References (57)

1. Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;96-102.
2. van der Hage JA, van de Velde CJ, Julien JP, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-4237.
3. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019-2027.
4. Gianni L, Baselga J, Eiermann W, et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol. 2009;27:2474-2481.
5. Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778-785.
6. Untch M, Mobus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 2009;27:2938-2945.
7. Earl HM, Vallier A, Hiller L, et al. Neo-tAnGo: a neoadjuvant randomized phase III trial of epirubicin/cyclophosphamide and paclitaxel ± gemcitabine in the treatment of women with high-risk early breast cancer (EBC): first report of the primary endpoint, pathological complete response (pCR). J Clin Oncol. 2009;27:15s (suppl; abstr 522).
8. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676-2685.
9. von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst. 2008;100:542-551.
10. von Minckwitz G, Rezai M, Loibl S, et al. Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28:2015-2023.
11. Strange RC, Spiteri MA, Ramachandran S, et al. Glutathione-S-transferase family of enzymes. Mutat Res. 2001;482:21-26.
12. Russo A, Mitchell JB. Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat Rep. 1985;69:1293-1296.
13. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene. 2003;22:7369-7375.
14. Knoop AS, Knudsen H, Balslev E, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005;23:7483-7490.
15. Burgess DJ, Doles J, Zender L, et al. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci USA. 2008;105:9053-9058.
16. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer. 2007;96:639-645.
17. Lu J, Tan M, Huang WC, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to taxol resistance. Clin Cancer Res. 2009;15:1326-1334.
18. Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977;39:1289-1294.
19. Ozmen V, Unal ES, Muslumanoglu ME, et al. Axillary sentinel node biopsy after neoadjuvant chemotherapy. Eur J Surg Oncol. 2010;36:23-29.
20. Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456-1466.
21. Kaufmann M, von Minckwitz G, Rody A. Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast. 2005;14: 576-581.
22. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-2685.
23. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165-4174.
24. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
25. Montagna E, Bagnardi V, Rotmensz N, et al. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features. Breast Cancer Res Treat. 2010;124:689-699.
26. Alvarado-Cabrero I, Alderete-Vazquez G, Quintal-Ramirez M, et al. Incidence of pathologic complete response in women treated with preoperative chemotherapy for locally advanced breast cancer: correlation of histology, hormone receptor status, Her2/Neu, and gross pathologic findings. Ann Diagn Pathol. 2009;13:151-157.
27. Calvert P, Yao KS, Hamilton TC, et al. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact. 1998;111-112:213-224.
28. Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65:437-446.
29. Nelson CP, Kidd LC, Sauvageot J, et al. Protection against 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine cytotoxicity and DNA adduct formation in human prostate by glutathione S-transferase P1. Cancer Res. 2001;61:103-109.
30. L'Ecuyer T, Allebban Z, Thomas R, et al. Glutathione S-transferase overexpression protects against anthracycline-induced H9C2 cell death. Am J Physiol Heart Circ Physiol. 2004;286:H2057-H2064.
31. Arai T, Miyoshi Y, Kim SJ, et al. Association of GSTP1 expression with resistance to docetaxel and paclitaxel in human breast cancers. Eur J Surg Oncol. 2008;34:734-738.
32. Schmidt M, Bachhuber A, Victor A, et al. p53 expression and resistance against paclitaxel in patients with metastatic breast cancer. J Cancer Res Clin Oncol. 2003;129:295-302.
33. Peters WH, Roelofs HM, van Putten WL, et al. Response to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases. Br J Cancer. 1993; 68:86-92.
34. Shin HJ, Sneige N, Sahin A, et al. Glutathione S-transferase-pi expression in prechemotherapy and postchemotherapy tumor samples from patients with locally advanced breast carcinomas. Breast J. 2007;2:246-252.
35. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005;200:336-344.
36. Feng Y, Hao X, Mao H. Clinical significance of MDR gene expression in malignant pleural effusion and ascites and solid tumors. Zhonghua Yi Xue Za Zhi. 2001;81:1484-1487.
37. Kellner U, Sehested M, Jensen PB, et al. Culprit and victim- DNA topoisomerase II. Lancet Oncol. 2002;3:235-243.
38. Coon JS, Marcus E, Gupta-Burt S, et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res. 2002;8:1061-1067.
39. Park K, Kim J, Lim S, et al. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003; 39:631-634.
40. Martin-Richard M, Munoz M, Albanell J, et al. Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy. Oncology. 2004; 66:388-394.
41. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients. Clinical Breast Cancer. 2007;7:445-454.
42. Orlando L, Del Curto B, Gandini S, et al. Topoisomerase II alpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Breast. 2008;17: 506-511.
43. Zhu L, Li YF, Chen WG, et al. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients. Chin Med J (Engl). 2008;121:1965-1968.
44. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer. 2004;40:205-211.
45. Rody A, Karn T, Gatje R, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast. 2007;16:86-93.
46. Mueller RE, Parkes RK, Andrulis I, et al. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer. 2004;39:288-297.
47. Sullivan DM, Latham MD, Ross WE. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res. 1987;47:3973-3979.
48. Tewari M, Krishnamurthy A, Shukla HS. Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol. 2008;17:301-311.
49. Tanaka K, Iwamoto S, Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6:127-134.
50. Yamashita S, Masuda Y, Kurizaki T, et al. Survivin expression predicts early recurrence in early-stage breast cancer. Anticancer Res. 2007;27:2803-2808.
51. Brennan DJ, Rexhepaj E, O'Brien SL, et al. Altered cytoplasmicto-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res. 2008;14:2681-2689.
52. Knauer SK, Kramer OH, Knosel T, et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J. 2007;21:207-216.
53. Zaffaroni N, Pennati M, Colella G, et al. Expression of the antiapoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci. 2002;59:1406-1412.
54. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95:92-95.
55. Vallbohmer D, Drebber U, Schneider PM, et al. Survivin expression in gastric cancer: association with histomorphological response to neoadjuvant therapy and prognosis. J Surg Oncol. 2009;99:409-413.
56. G Estevez L, Fortes JL, Adrover E, et al. Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study. Clin Transl Oncol. 2009;11:54-59.
57. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med. 2009;23:285-291.